

**Complete if Known**


(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	09/925,224
<b>Filing Date</b>	08/09/2001
<b>First Named Inventor</b>	Timothy L. MA
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Sudhaker Patel
<b>Attorney Docket Number</b>	00399-12

DEC 18 2001  
TECH CENTER 1 600/2900

RECEIVED



## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Good Luck 13/6/21

Date Considered

$$2 \mid 23 \mid 52$$

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT




(use as many sheets as necessary)

Sheet 1 of 1


### Complete if Known

Application Number	09/925,224
Filing Date	08/09/2001
First Named Inventor	Timothy L. MACDONALD
Group Art Unit	1614
Examiner Name	Sudhaker Patel
Attorney Docket Number	00399-12

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	M. G. O'NEIL, ET AL., "Felbamate-associated fatal acute hepatic necrosis," Neurology, 46, pp. 1457-1459, (May 1996)	
	B	Y. M. CHOI, ET AL., "Metabolites of Felbamate: Synthesis of 2-(4-Hydroxyphenyl)-1,3-Propanediol Dicarbamate, 2-Phenyl-2-Hydroxy-1, 3-Propanediol Dicarbamate, and 2-Phenyl-1,3-Propanediol Monocarbamate," Tetrahedron, 42 (23), pp. 6399-6404, (1986)	
	C	P. B. PENNELL, ET AL., "Aplastic anemia in a patient receiving felbamate for complex partial seizures," Neurology, 45, pp. 456-460, (March 1995)	

Examiner  
Signature



Date  
Considered



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box:

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	09/925,224
Filing Date	08/09/2001
First Named Inventor	Timothy L. MACDONALD
Group Art Unit	1614
Examiner Name	Sudhaker Patel
Attorney Docket Number	00399-12

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>	A	DAVID E. BURDETTE, ET AL., "Felbamate Pharmacology and Use in Epilepsy," Clinical Neuropharmacology, Vol. 17 (No. 5), p. 389-402, (December 17, 1994). 1	
<i>[Signature]</i>	B	DIETER SCHMIDT, "Felbamate: Successful Development of a New Compound for the Treatment of Epilepsy," Epilepsia, Vol. 34 (No. 7), p. S30-S33, (December 17, 1993). 2	
<i>[Signature]</i>	C	R. DUANE SOFIA, PH.D., "Mechanism of Action of the Anticonvulsant Felbamate: Opposing Effects on N-Methyl-D-Aspartate and Y-Aminobutyric Acid A Receptors," Anal. of Neurology, Vol. 36 (No. 4), p. 677-678, (October 1, 1994). 3	
<i>[Signature]</i>	D	A. SHUAIB, ET AL., "Neuroprotection with felbamate: a 7- and 28-day study in transient forebrain ischemia in gerbils," Brain Research, p. 65-70, (March 12, 1996). 4	
<i>[Signature]</i>	E	D. W. KAUFMAN, ET AL., "Evaluation of Case Reports of Aplastic Anemia Among Patients Treated with Felbamate," Epilepsia, Vol. 38 (No. 12), p. 1265-1269, (July 30, 1997). 5	
<i>[Signature]</i>	F	J. T. YANG, ET AL., "Felbamate Metabolism in the Rat, Rabbit, and Dog," Drug Metabolism and Disposition, Vol. 19 (No. 6), p. 1126-1134, (December 17, 1991). 6	
<i>[Signature]</i>	G	V. E. ADUSUMALLI, ET AL., "Isolation and Identification of 3-Carbamoyloxy-2-Phenylpropionic Acid as a Major Human Urinary Metabolite of Felbamate," Drug Metabolism and Disposition, Vol. 21 (No. 4), p. 710-716, (March 26, 1993). 2	

Examiner  
Signature

*[Signature]*

Date  
Considered

2/23/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



